Mepolizumab

Generic Name
Mepolizumab
Brand Names
Nucala
Drug Type
Biotech
Chemical Formula
-
CAS Number
196078-29-2
Unique Ingredient Identifier
90Z2UF0E52
Background

Eosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typically defined as absolute eosinophil levels of 1500/mm or more) is associated with a spectrum of diseases, including severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). The pathogenesis of eosinophilia is comp...

Indication

Mepolizumab is an anti-IL-5 IgG1 kappa monoclonal antibody indicated as an add-on maintenance treatment in patients aged six years and older with severe eosinophilic asthma and as a treatment in adult patients for eosinophilic granulomatosis with polyangiitis (EGPA). Mepolizumab is also indicated for the treatment of hypereosinophilic syndrome (HES) in patie...

Associated Conditions
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Hypereosinophilic Syndrome (HES), Severe Eosinophilic Asthma
Associated Therapies
-
Clinical Trials
Related News

Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

First Posted Date
2019-10-21
Last Posted Date
2024-12-11
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
806
Registration Number
NCT04133909
Locations
🇬🇧

GSK Investigational Site, Wishaw, United Kingdom

Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial

Phase 2
Completed
Conditions
COPD
Eosinophilia
Interventions
Drug: Placebo
Drug: Mepolizumab
First Posted Date
2019-08-30
Last Posted Date
2024-07-01
Lead Sponsor
University of Leicester
Target Recruit Count
238
Registration Number
NCT04075331
Locations
🇬🇧

NIHR Biomedical Research Centre, Respiratory, Leicester, Leicestershire, United Kingdom

Effect of Mepolizumab on Decrease of Systemic Corticosteroids in Patients With Severe Eosinophilic Asthma

Completed
Conditions
Asthma; Eosinophilic
Interventions
Drug: Mepolizumab
First Posted Date
2018-03-02
Last Posted Date
2018-10-03
Lead Sponsor
University Hospital, Grenoble
Target Recruit Count
27
Registration Number
NCT03453021
Locations
🇫🇷

University Hospital Grenoble, La Tronche, France

A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622

Phase 3
Completed
Conditions
Hypereosinophilic Syndrome
Interventions
Drug: Mepolizumab
First Posted Date
2017-10-10
Last Posted Date
2020-06-23
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
102
Registration Number
NCT03306043
Locations
🇬🇧

GSK Investigational Site, Leicester, United Kingdom

Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921

First Posted Date
2017-09-29
Last Posted Date
2024-03-12
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
100
Registration Number
NCT03298061
Locations
🇬🇧

GSK Investigational Site, Leicester, United Kingdom

Study of Mepolizumab Autoinjector in Asthmatics

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Mepolizumab
First Posted Date
2017-04-04
Last Posted Date
2023-06-28
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
159
Registration Number
NCT03099096
Locations
🇬🇧

GSK Investigational Site, Southampton, United Kingdom

Effect of Mepolizumab in Severe Bilateral Nasal Polyps

First Posted Date
2017-03-21
Last Posted Date
2021-08-03
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
414
Registration Number
NCT03085797
Locations
🇬🇧

GSK Investigational Site, Rotherham, United Kingdom

Study of Mepolizumab Safety Syringe in Asthmatics

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Mepolizumab
First Posted Date
2017-01-13
Last Posted Date
2019-07-23
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
56
Registration Number
NCT03021304
Locations
🇸🇪

GSK Investigational Site, Stockholm, Sweden

Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study

Phase 3
Terminated
Conditions
Asthma
Interventions
Drug: Mepolizumab
Drug: Placebo
First Posted Date
2015-11-03
Last Posted Date
2017-07-13
Lead Sponsor
Johannes Gutenberg University Mainz
Target Recruit Count
29
Registration Number
NCT02594332
Locations
🇩🇪

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Pneumologie, Mainz, Germany

Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: Mepolizumab
First Posted Date
2015-03-03
Last Posted Date
2019-12-03
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
36
Registration Number
NCT02377427
Locations
🇬🇧

GSK Investigational Site, Sheffield, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy